Perhaps of most significance is the ERA-resistant heart failure resulting from cardiac over expression of human EDN1 in mice, where combined ETA- and ETB-antagonist treatment failed to prevent the lethal effects of this transgenic modification7. The gene discussed is EDN1; the disease is heart failure.